

Applicants : Hilton A. Salhanick and Joachim Hourihan  
U.S. Serial No: 09/915,931  
Filed : July 26, 2001  
Page 2

132. (New) The method of any one of claims 33, 94, 102, 110 and 123, wherein the urine sample is concentrated.

133. (New) The method of any one of claims 33, 94, 102, 110 and 123, wherein the urine sample is not concentrated.

*C1  
cons* 134. (New) The method of claim 99 or 115, wherein the detectable marker is selected from the list comprising a colorimetric marker, a luminescent marker and a fluorescent marker.

135. (New) The method of any one of claims 103, 104, 116, 117, 124 and 125, wherein the detectable thyroxine is labeled with a detectable marker selected from the list comprising a colorimetric marker, a luminescent marker, and a fluorescent marker.

---

REMARKS

Claims 1, 2, 9-11, 17-19, 25-27, 33-35, 41, 42, 47, 48, 54, 55, 60, 61, 67, 68, 74-76, 81-83 and 88 are pending in the subject application. By the Amendment submitted on March 5, 2003, applicants have cancelled claims 1, 2, 25-27, 54, 55, 60, 61 and 81-83 without prejudice or disclaimer and added new claims 94-129. By this Supplemental Amendment, applicants have added new claims 130-135. After entry of both the March 5, 2003 Amendment and this Supplemental Amendment, claims 9-11, 17-19, 33-35, 41, 42, 47, 48, 67, 68, 74-76, 88 and 94-135 will be pending, and claims 33-35 and 94-135 will be under examination. New claims 130-133 correspond to canceled claims 89-92, respectively. New claims 134 and 135 correspond to canceled claim 93. Applicants maintain that the addition of new claims 130-135 raises no issue of new matter and is fully supported by the specification as